公司资料
Rezolute 股价、新闻与催化剂
- 股票代码:
- RZLT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
5.01 USD (-1.57%)
收盘价
最后更新: 2026年8月24日
385M USD
市值
股价为何变动
As of Aug 24, 2026, RZLT closed down 1.57% at $5.01. No new same-company headline was identified in the current news window.
公司概览
业务概览
Rezolute is a rare-disease and endocrine company focused on hypoglycemia and metabolic disorders. Its programs target difficult hormonal diseases with few effective therapies.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Rezolute sits in specialty biotechnology.
商业模式特征
The business depends on clinical data, dose strategy, and the chance to build value in rare endocrine disease.
生物医药行业定位
Rezolute is a small-cap rare-disease catalyst name whose valuation depends on proof-of-concept and execution.
未来催化剂
- Rezolute’s catalyst is ersodetug in hyperinsulinism, where each clinical and regulatory step can materially change the valuation. The market will care about whether the program keeps moving toward a real rare-disease opportunity.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。